How buyers actually evaluate healthcare companies

You've built the growth. Here's the evaluation it has to survive.

There's a number every healthcare CEO carries in their head: what the business should be worth. Then there's the number the buyer offers.

The distance between those two numbers is rarely about the quality of the business. It's about the legibility of that quality under scrutiny. A buyer can't pay for what they can't verify, and they won't pay a premium for anything they have to take on faith.

Most operators discover this inside diligence, when it's too late to change the answer. The ones who command premium outcomes discovered it 18 to 36 months earlier, because they learned to evaluate their company the way a buyer would. That's the discipline we call the Buyer's Eye View, and the structure behind it is the Buyer Evaluation Model, Stage 5 of the Enterprise Value Creation System™.

The premise buyers won't say out loud

Founders tend to believe buyers are evaluating potential. They're not. Buyers are evaluating durability. Before a sophisticated acquirer, whether strategic or financial, spends a single cycle on your upside, they're asking a colder question: what could go wrong here, and has this team already made those risks visible, documented, and manageable?

This isn't cynicism. It's arithmetic. Most healthcare companies are valued as a multiple of earnings, and that multiple is fundamentally a confidence score. When a buyer discounts your multiple, they're not insulting your business. They're pricing their uncertainty.

So, the entire game of exit value comes down to this: reduce the buyer's uncertainty before they find it themselves. The Buyer Evaluation Model maps where that uncertainty lives. Four lenses, evaluated in sequence, that determine whether a buyer sees a premium acquisition or a discounted project.

Lens 1: Market story – narrative, category, and strategic fit

The first lens is the one most companies over-invest in, because it's the one they control most directly: the story.

But buyers don't evaluate your narrative the way your marketing team does. They're testing three things. Is the category real and durable? Is the strategic fit obvious, making their existing thesis stronger? And does the narrative survive contact with the operating reality, or dissolve the moment they interview a customer?

Here's the trap: a polished story with nothing underneath doesn't just fail this lens. It contaminates the other three. The moment a buyer catches daylight between claim and data, every subsequent claim gets audited harder. A strong market story isn't a better deck. It's a narrative so aligned with the business that diligence confirms it instead of eroding it. 

Lens 2: Revenue quality – mix, margin, and customer concentration

If the market story earns attention, revenue quality determines whether the buyer trusts the money. Not all revenue is worth the same. A dollar of diversified, high-margin, contracted revenue and a dollar of concentrated, relationship-dependent revenue look identical on the income statement, yet completely different through a buyer's lens.

The questions are surgical. What's the mix of recurring versus one-time revenue? Is margin structural or circumstantial? And the one that quietly kills more healthcare deals than any other: how concentrated is the customer base?

This is where it gets personal. That flagship health system contract you celebrate internally is read by a buyer as 40% of revenue exposed to a single renewal decision. Same fact, opposite conclusion. That inversion is the Buyer's Eye View in miniature. 

Lens 3: Revenue predictability – recurring base and forecast reliability

The third lens moves from what the revenue is to whether it repeats. Buyers aren't purchasing your history. They're purchasing your future cash flows, and they'll only pay a premium for a future they can underwrite.

So, they test the machinery. Does a recurring base exist, or does the company re-earn its revenue from scratch every year? Do forecasts have a track record of accuracy, or is the pipeline a mood? Does growth trace to a system, or to founder heroics and fortunate timing?

This is the lens where “we're growing fast” goes to die. Momentum is precisely what buyers refuse to pay for, because momentum stops the day ownership changes. They reward a documented, repeatable, transferable commercial system. If you can't show the system, the buyer assumes there isn't one, and prices accordingly. 

Lens 4: Risk – key-person, market, and operational exposure

The final lens is the narrowest point of the funnel: everything that could break after the wire clears.

Key-person exposure leads the list, and in founder-led healthcare companies it's nearly universal. If the clinical credibility, payer relationships, and objection handling all route back to one person, the buyer isn't acquiring a company. They're acquiring a dependency, and they'll structure the deal to protect themselves: earnouts, escrows, extended transitions, compressed multiples. Every deal term you'll hate is a risk you left unaddressed.

Market and operational exposure round out the lens: reimbursement dependencies, regulatory concentration, single-vendor bottlenecks. None show up in your pitch. All show up in diligence. The companies that clear this lens didn't eliminate risk. They found it first, documented it, and built the mitigation before anyone asked.

Why the sequence is the strategy

Notice the shape of the model: it's a funnel, not a checklist. Market story at the top, risk at the bottom, and the valuation multiple, premium or discount, as the output.

The sequence matters because each lens gates the next. A compelling story earns scrutiny of your revenue. Quality revenue earns scrutiny of its predictability. Fail early and the buyer never invests the effort to see your strengths. Fail late and they've already built conviction, which is why late-stage surprises don't just lower the price. They poison the trust the deal rests on.

And here's the asymmetry that explains most valuation disappointment: nearly every company optimizes one or two lenses and leaves the others unattended. The gap between the number you expected and the offer you received almost always lives in the lens you weren't watching.

The model in the wild

If you want to see all four lenses working in one company, look at Meghan Gaffney. When she founded Veda to fix healthcare's provider data problem, investors passed. Directories weren't a category anyone wanted a story about.

But she was building a company shaped exactly like the funnel: a market story rooted in a problem every payer provably had. Revenue earned across the largest health plans in the country, on measurable accuracy no manual vendor could match. Predictability driven by regulatory mandate. And a risk profile of pure infrastructure: essential, and independent of any one person's charisma.

By the time Veda was acquired in 2025, there was nothing for a buyer to squint at. The value wasn't argued. It was evident. Her full story is one of eleven we tell in Winning in Healthcare, because the pattern isn't unique to her. It's the pattern. 

Where to start

You can't fix all four lenses at once, and you shouldn't try. The work starts with an honest audit: run your business through the funnel the way a buyer will, and find the lens where your discount is currently hiding.

For most founder-led companies, it's key-person risk. For most fast-growth companies, it's predictability. For most well-run operational companies, it's a market story that's never been institutionalized. Wherever yours is, every month it goes unaddressed is a month closer to discovering it inside diligence, where it costs the most and can be fixed the least.

The exit is won long before the process begins. The only question is whether you're doing the buyer's evaluation now, on your terms, or later, on theirs.

Explore the full Buyer Evaluation Model and the Enterprise Value Creation System™ it belongs to: legacy-dna.com/buyer-evaluation

Read the stories behind the framework in Winning in Healthcare: How the Best Builders Turn Growth Into Enterprise Value, now available on Amazon.

Ready to find your hidden discount? Schedule a Strategic Fit Call with Dr. Roxie Mooney: legacy-dna.com/strategic-fit-call